(Q46340832)

21 December 2017

title

The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation (English)

1 reference

21 December 2017

main subject

organ transplantation

1 reference

1 reference

Avinash Agarwal

1

1 reference

21 December 2017

Luke Y Shen

series ordinal

2

1 reference

21 December 2017

Allan D Kirk

series ordinal

3

1 reference

21 December 2017

publication date

29 September 2008

1 reference

21 December 2017

published in

Transplant Immunology

1 reference

21 December 2017

volume

20

1 reference

21 December 2017

issue

1-2

1 reference

21 December 2017

page(s)

6-11

1 reference

21 December 2017

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Immunosuppression: evolution in practice and trends, 1994-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Immunosuppressive medications for renal transplantation: a multiple choice question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

What's in the pipeline? New immunosuppressive drugs in transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Infection in solid-organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Liver transplantation in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Association of Herpesvirus Infections with T-Lymphocyte-Subset Alterations, Glomerulopathy, and Opportunistic Infections after Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Five preventable causes of kidney graft loss in the 1990s: a single-center analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Cardiovascular toxicities of immunosuppressive agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Hyperlipidemia in solid organ transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Induction immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Effect of anti-lymphocyte antibody induction therapy on renal allograft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Daclizumab to prevent rejection after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Tolerogenic immunosuppression for organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

The CAMPATH-1 antigen (CDw52)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

The immunogenicity of chimeric antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

CAMPATH: from concept to clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Reshaping human antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Campath-1H in renal transplantation: The University of Wisconsin experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Campath induction for kidney transplantation: report of 297 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

The impact of Campath 1H induction in adult liver allotransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Intestinal and multivisceral transplantation in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Pediatric liver transplant with Campath 1H induction--Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Campath-1H use in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.09.003

10.1016/J.TRIM.2008.09.003

7 January 2021

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

18824230

1 reference

21 December 2017